Analysis of Factors Affecting Hematopoietic Stem Cell Mobilization Efficiency and Early Hematopoietic Reconstruction Indicators during Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Abstract

Purpose To analyze the factors affecting the mobilization efficiency of hematopoietic stem cells and hematopoietic reconstruction indicators during autologous peripheral hematopoietic stem cell transplantation.
Methods The clinical data of 54 patients who underwent autologous peripheral blood hematopoietic stem cell mobilization and transplantation at Xuzhou Central Hospital from May 2016 to April 2023 were retrospectively analyzed. The gender, age, disease type, mobilization regimen, number of chemotherapy sessions, G-CSF (granulocyte colony-stimulating factor) dosage, and platelet number at the time of collection were also collected. Moreover, the relationship between these indicators with mobilization results and hematopoietic reconstruction was analyzed.
Results Results showed that age, disease type, and number of collections were significantly related to the mobilization results (number of CD34+ hematopoietic stem cells). Furthermore, multivariate analysis showed that the number of collections was an independent factor affecting mobilization efficiency. Similarly, age, platelet value at the time of collection, CD34+ stem cell value during collection, white blood cell count, and number of chemotherapy times were significantly related to the time of megakaryocytic hematopoietic reconstruction. Multifactor analysis found that age and platelet count were independent factors affecting the reconstruction time of the megakaryocytic system. However, no factor was related to the time of granulocyte hematopoietic reconstruction.
Conclusion Platelet count and age when collecting hematopoietic stem cells are closely related to megakaryocytic hematopoietic reconstruction and are key indicators of early hematopoietic reconstruction after autologous hematopoietic stem cell transplantation.

Keywords

autologous stem cell transplantation / peripheral blood stem cell / platelet value at the time of collection / megakaryocytic hematopoietic reconstruction

References

[[1]] Chinese expert consensus on mobilization and collection of autologous hematopoietic stem cells for lymphoma. Zhonghua Xue Ye Xue Za Zhi 2020; 41(12) 979-983

[[2]] Chinese guidelines for the diagnosis and treatment of multiple myeloma (2020 revision). Chin J Integr Med 2020; 59(05) 1-6

[[3]] Wei X, Wei Y.Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments. Ann Hematol 2023; 102(05) 995-1009

[[4]] Han X, Ma L, Zhao L.et al.Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. J Clin Apher 2012; 27(02) 64-74

[[5]] Zheng G, He J, Cai Z.et al.A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett 2020; 19(01) 1051-1059

[[6]] Ishii A, Jo T, Arai Y.et al.Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. Cytotherapy 2022; 24(01) 49-58

[[7]] Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev 2014; 28(01) 31-40

[[8]] Giralt S, Costa L, Schriber J.et al.Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20(03) 295-308

[[9]] Olivieri A, Marchetti M, Lemoli R. et al. Italian Group for Stem Cell Transplantation. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47(03) 342-351

[[10]] DiPersio JF, Micallef IN, Stiff PJ.et al. 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27(28) 4767-4773

[[11]] DiPersio JF, Stadtmauer EA, Nademanee A.et al. 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113(23) 5720-5726

[[12]] Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012; 26(01) 34-53

[[13]] Ratajczak MZ, Lee H, Wysoczynski M.et al.Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010; 24(05) 976-985

[[14]] Civriz Bozdag S, Tekgunduz E, Altuntas F.The current status in hematopoietic stem cell mobilization. J Clin Apher 2015; 30(05) 273-280

[[15]] Stiff PJ, Micallef I, Nademanee AP.et al.Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011; 17(08) 1146-1153

[[16]] Hassan MN, Fauzi HM, Husin A.et al.Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment. Oman Med J 2019; 34(01) 34-43

[[17]] Gifford G, Hesson L, Wong JWH.et al.Poor mobilization of autologous CD34+ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. Br J Haematol 2021; 193(04) 841-844

[[18]] Lutfi F, Skelton Iv WP, Wang Y.et al.Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. Hematol Oncol Stem Cell Ther 2020; 13(01) 23-31

[[19]] Miyamoto-Nagai Y, Mimura N, Tsukada N.et al.Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: a multicenter retrospective study in Japan. EJHaem 2022; 3(03) 838-848

[[20]] Ma Y.et al.Clinical study of eltrombopag in the treatment of refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi 2016; 37(12) 1065-1069

[[21]] Zhu L, Liu J, Kong P.et al.Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Front Immunol 2022; 13: 910893

RIGHTS & PERMISSIONS

2024 Global Medical Genetics